目的 探討大活絡(luò)膠囊聯(lián)合阿加曲班注射液治療急性腦梗死患者的臨床療效。方法 選取2020年1月—2021年1月在天津市南開醫(yī)院進(jìn)行治療的82例急性腦梗死患者，根據(jù)用藥差別分為對(duì)照組和治療組，每組各41例。對(duì)照組給予阿加曲班注射液，初始劑量60 mg/d，同0.9%氯化鈉注射液500 mL配伍，持續(xù)24 h靜脈點(diǎn)滴，其后20 mg/次同0.9%氯化鈉注射液150 mL配伍，2次/d，每次靜脈滴注3 h；治療組在對(duì)照組基礎(chǔ)上口服大活絡(luò)膠囊，1 g/次，3次/d。兩組均經(jīng)14 d治療。觀察兩組的臨床療效，比較兩組相關(guān)評(píng)分、血管內(nèi)皮功能指標(biāo)的變化情況。結(jié)果 治療后，治療組總有效率97.56%，顯著高于對(duì)照組的80.49%（P<0.05）。治療后，兩組NIHSS評(píng)分、MRS評(píng)分均顯著降低，但ADL評(píng)分、MoCA評(píng)分顯著升高（P<0.05）；治療后，治療組相關(guān)評(píng)分改善優(yōu)于對(duì)照組（P<0.05）。經(jīng)治療，兩組血清一氧化氮（NO）、血管生成素（Ang-1）、降鈣素基因相關(guān)肽（CGRP）均顯著升高，但血管性假血友病因子（vWF）、血栓調(diào)節(jié)蛋白（TM）、血管內(nèi)皮細(xì)胞鈣黏蛋白（VE-cadherin）、內(nèi)皮素-1（ET-1）水平降低（P<0.05）；治療后，治療組患者血管內(nèi)皮功能指標(biāo)改善優(yōu)于對(duì)照組（P<0.05）。結(jié)論 大活絡(luò)膠囊聯(lián)合阿加曲班注射液治療急性腦梗死患者具有較好的臨床療效，可促進(jìn)神經(jīng)功能恢復(fù)，改善患者血管內(nèi)皮功能，促進(jìn)患者日?；顒?dòng)能力提高，有著良好的臨床應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Dahuoluo Capsules combined with argatroban in treatment of acute cerebral infarction. Methods A total of 82 patients with acute cerebral infarction who were treated in Tianjin Nankai Hospital from January 2020 to January 2021 were selected and divided into control group and treatment group according to drug difference, with 41 cases in each group. The control group were iv administered with Argatroban Injection, initially 60 mg/d, mixed with 0.9% sodium chloride injection 500 mL, intravenous drip for 24 h, then 20 mg/time, mixed with 0.9% sodium chloride injection 150 mL, twice daily, intravenous drip for 3 h each time. The treatment group po administered with Dahuoluo Capsules on the basis of the control group, 1 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the changes of related scores and vascular endothelial function indexes were compared between the two groups. Results After treatment, the total effective rate of treatment group was 97.56%, which was significantly higher than that of control group (80.49%) (P < 0.05). After treatment, NIHSS score and MRS score in two groups were significantly decreased, but ADL score and MoCA score were significantly increased (P < 0.05). After treatment, the improvement of relevant scores in treatment group was better than that in control group (P < 0.05). After treatment, serum nitric oxide (NO), angogenin (ANG-1), and calcitonin gene-related peptide (CGRP) in two groups were significantly increased. However, the levels of von Willebrand factor (vWF), thrombomregulatory protein (TM), vascular endothelial cell cadherin (VE-Cadherin), and endothelin-1 (ET-1) were decreased (P < 0.05). After treatment, the improvement of vascular endothelial indices in the treatment group was better than that in the control group (P < 0.05). Conclusion Dahuoluo Capsules combined with argatroban has good clinical effect in treatment of acute cerebral infarction, and can promote the recovery of neurological function, improve the vascular endothelial function of patients, promote the improvement of daily activities, which has good clinical application value.

R971